Axa S.A. Acquires 62,376 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

AXA S.A. lifted its position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 400.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,970 shares of the company's stock after acquiring an additional 62,376 shares during the period. AXA S.A.'s holdings in Dr. Reddy's Laboratories were worth $1,231,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC grew its holdings in shares of Dr. Reddy's Laboratories by 109.3% in the 3rd quarter. Geode Capital Management LLC now owns 13,254 shares of the company's stock valued at $1,053,000 after buying an additional 6,920 shares during the period. GAMMA Investing LLC increased its holdings in shares of Dr. Reddy's Laboratories by 369.9% in the fourth quarter. GAMMA Investing LLC now owns 6,799 shares of the company's stock worth $107,000 after acquiring an additional 5,352 shares in the last quarter. Nordea Investment Management AB raised its position in shares of Dr. Reddy's Laboratories by 441.8% during the fourth quarter. Nordea Investment Management AB now owns 125,363 shares of the company's stock worth $1,992,000 after purchasing an additional 102,226 shares during the period. Aprio Wealth Management LLC lifted its holdings in shares of Dr. Reddy's Laboratories by 515.6% during the 4th quarter. Aprio Wealth Management LLC now owns 18,807 shares of the company's stock valued at $297,000 after purchasing an additional 15,752 shares in the last quarter. Finally, Harbour Capital Advisors LLC increased its stake in Dr. Reddy's Laboratories by 400.0% during the 4th quarter. Harbour Capital Advisors LLC now owns 25,100 shares of the company's stock worth $388,000 after purchasing an additional 20,080 shares in the last quarter. Institutional investors own 3.85% of the company's stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a report on Thursday.

Dr. Reddy's Laboratories Stock Up 1.8 %

Dr. Reddy's Laboratories stock traded up $0.24 during midday trading on Friday, reaching $13.42. The stock had a trading volume of 2,669,798 shares, compared to its average volume of 1,487,128. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy's Laboratories Limited has a 1-year low of $12.26 and a 1-year high of $16.89. The stock has a market capitalization of $11.20 billion, a P/E ratio of 21.37 and a beta of 0.33. The firm's fifty day simple moving average is $13.29 and its 200-day simple moving average is $14.06.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The firm had revenue of $996.17 million for the quarter, compared to analyst estimates of $83.70 billion. As a group, analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.